The new antitumor mRNA vaccine "Neoonkovak" gave the first results of treatment, said Alexander Ginzburg, director of the Gamaleya Center, Academician of the Russian Academy of Sciences.
"There are small shifts in terms of the production of the necessary cytokines," he said.
According to Ginzburg, immunological results will be evaluated later, as the vaccine will be administered to the patient about ten more times.
In early April, it became known that the drug "Neoonkovak" was first administered to a 60-year-old resident of the Kursk region with skin melanoma. The man is undergoing treatment and is now under observation at home.
The vaccine is made individually for each person, the drug contains information about specific tumor antigens, which allows you to "tune" the patient's immune system to recognize and destroy, including microscopic foci of tumors. The vaccine is available by compulsory medical insurance.

Coal ran aground in Europe
Macron urged the French to prepare for war
NYT: IRGC arrested ex-Iranian President Ahmadinejad for collaborating with Mossad
Cinemas in Russia were advised to postpone the premiere of the new "Spider-Man"
In Turkey, the hotel manager tried to commit suicide due to the absence of Russians
Putin: We will respond in a mirror way, only several times more powerful — they will feel